SeaBridge Investment Advisors LLC Sells 2,353 Shares of Thermo Fisher Scientific Inc. $TMO

SeaBridge Investment Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 40.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,493 shares of the medical research company’s stock after selling 2,353 shares during the quarter. SeaBridge Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,751,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of TMO. Legacy Wealth Managment LLC ID lifted its stake in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares during the last quarter. Allied Private Wealth LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $26,000. High Note Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. Finally, JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter worth about $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Royal Bank Of Canada lifted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Piper Sandler raised their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Insider Activity

In other news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 52,053 shares of company stock worth $30,643,589. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.0%

Shares of NYSE TMO opened at $588.17 on Monday. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The business has a fifty day moving average price of $529.37 and a 200 day moving average price of $508.75. The stock has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the company posted $4.28 earnings per share. The firm’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.